image of Daniel Minter
ucsf logo

Daniel Minter, MD

He | Him | HisInfectious Diseases
Neuro-Infectious Diseases Parnassus
415-353-2626
image of Daniel Minter
image of Daniel Minter
ucsf logo

Daniel Minter, MD

He | Him | HisInfectious Diseases
Neuro-Infectious Diseases Parnassus
415-353-2626

On this page

About me

Dr. Daniel Minter is an infectious disease specialist who cares for patients with a broad range of bacterial, fungal, viral and parasitic infections. He has special interests in caring for immunocompromised patients and those with infections that affect the nervous system.

Minter's research interests include medical education and clinical reasoning (the thought processes through which care providers diagnose conditions and develop treatment plans). He teaches medical students, residents and fellows in a variety of settings.

Minter earned his medical degree at UCSF, where he also completed a residency in internal medicine and a fellowship in infectious diseases.

Education

Board Certification

  • Infectious Disease, American Board of Internal Med/Infectious Disease
  • Internal Medicine, American Board of Internal Medicine

Fellowship

  • Infectious Diseases, UCSF School of Medicine -GME

Residency

  • Internal Medicine, UCSF School of Medicine -GME

Internship

  • Internal Medicine, UCSF School of Medicine -GME

School

  • MD, UCSF School of Medicine

Academic Title

  • Clinical Professor

Care Keywords

  • Services
    • Infectious Diseases

Locations

    Provider Research Listing

    Browse clinical trials and publications by this provider

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.

    The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.